SYK inhibitor

DRUG CLASS:

SYK inhibitor

News alerts, weekly reports and conference planners

Related drugs:

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B	HM43239 Sensitive: B - Late Trials HM43239 Sensitive : B
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	GS-9876 Sensitive: C2 – Inclusion Criteria GS-9876 Sensitive : C2	GS-9876 Sensitive: C2 – Inclusion Criteria GS-9876 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2	GS-9973 Sensitive: C2 – Inclusion Criteria GS-9973 Sensitive : C2
KRAS mutation	Childhood B Acute Lymphoblastic Leukemia	KRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
MEIS1 overexpression	Acute Myelogenous Leukemia	MEIS1 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
HOXA9 overexpression	Acute Myelogenous Leukemia	HOXA9 overexpression	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
SF3B1 mutation	Chronic Lymphocytic Leukemia	SF3B1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
NOTCH1 mutation	Chronic Lymphocytic Leukemia	NOTCH1 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3	obinutuzumab + GS-9973 Sensitive: C3 – Early Trials obinutuzumab + GS-9973 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
FLT3 wild-type	Acute Myelogenous Leukemia	FLT3 wild-type	Acute Myelogenous Leukemia	HM43239 Sensitive: C3 – Early Trials HM43239 Sensitive : C3	HM43239 Sensitive: C3 – Early Trials HM43239 Sensitive : C3
FLT3‐ITD + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD + NPM1 mutation	Acute Myelogenous Leukemia	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3	GS-9973 Sensitive: C3 – Early Trials GS-9973 Sensitive : C3
PTPN6 negative	Diffuse Large B Cell Lymphoma	PTPN6 negative	Diffuse Large B Cell Lymphoma	venetoclax + fostamatinib Sensitive: D – Preclinical venetoclax + fostamatinib Sensitive : D	venetoclax + fostamatinib Sensitive: D – Preclinical venetoclax + fostamatinib Sensitive : D
BCL2 positive	Diffuse Large B Cell Lymphoma	BCL2 positive	Diffuse Large B Cell Lymphoma	venetoclax + fostamatinib Sensitive: D – Preclinical venetoclax + fostamatinib Sensitive : D	venetoclax + fostamatinib Sensitive: D – Preclinical venetoclax + fostamatinib Sensitive : D
FLT3 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	FLT3 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D
FLT3 mutation + MLL mutation	Acute Myelogenous Leukemia	FLT3 mutation + MLL mutation	Acute Myelogenous Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D
BTK C481S	Chronic Lymphocytic Leukemia	BTK C481S	Chronic Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MYB-TYK2 fusion	B Acute Lymphoblastic Leukemia	MYB-TYK2 fusion	B Acute Lymphoblastic Leukemia	ALXN2075 Sensitive: D – Preclinical ALXN2075 Sensitive : D	ALXN2075 Sensitive: D – Preclinical ALXN2075 Sensitive : D
IL22 overexpression	B Acute Lymphoblastic Leukemia	IL22 overexpression	B Acute Lymphoblastic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL-AFF1 fusion	Acute Lymphocytic Leukemia	MLL-AFF1 fusion	Acute Lymphocytic Leukemia	selumetinib + GS-9973 Sensitive: D – Preclinical selumetinib + GS-9973 Sensitive : D	selumetinib + GS-9973 Sensitive: D – Preclinical selumetinib + GS-9973 Sensitive : D
MLL-AFF1 fusion + KRAS mutation	Acute Lymphocytic Leukemia	MLL-AFF1 fusion + KRAS mutation	Acute Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL-AFF1 fusion + NRAS mutation	Acute Lymphocytic Leukemia	MLL-AFF1 fusion + NRAS mutation	Acute Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL-MLLT3 fusion	Acute Lymphocytic Leukemia	MLL-MLLT3 fusion	Acute Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL-AFF1 fusion	Acute Lymphocytic Leukemia	MLL-AFF1 fusion	Acute Lymphocytic Leukemia	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D	GS-9973 Sensitive: D – Preclinical GS-9973 Sensitive : D
MLL rearrangement	Acute Lymphocytic Leukemia	MLL rearrangement	Acute Lymphocytic Leukemia	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D	CB-659 Sensitive: D – Preclinical CB-659 Sensitive : D
MYB-TYK2 fusion	B Acute Lymphoblastic Leukemia	MYB-TYK2 fusion	B Acute Lymphoblastic Leukemia	vorinostat + ALXN2075 Sensitive: D – Preclinical vorinostat + ALXN2075 Sensitive : D	vorinostat + ALXN2075 Sensitive: D – Preclinical vorinostat + ALXN2075 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	EC-70124 Sensitive: D – Preclinical EC-70124 Sensitive : D	EC-70124 Sensitive: D – Preclinical EC-70124 Sensitive : D

SYK inhibitor

SYK inhibitor

Associations(34)

Associations
(34)